Trial Profile
A Phase 2, Randomized, Open Label, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Rivaroxaban Compared With Vitamin K Antagonism in Patients With Atrial Fibrillation With Bioprosthetic Mitral Valves
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Apr 2022
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Warfarin
- Indications Embolism and thrombosis; Stroke; Transient ischaemic attacks
- Focus Adverse reactions; Therapeutic Use
- Acronyms RIVER
- 06 Apr 2021 Primary endpoint (Cardiovascular mortality or thromboembolic events) has been met, according to results published in the Annals of Internal Medicine.
- 06 Apr 2021 Status changed to completed as per results published in the Annals of Internal Medicine.
- 06 Apr 2021 Results assessing non-inferiority of rivaroxaban to warfarin for a composite of all-cause mortality, major cardiovascular (CV) events, or major bleeding in patients with atrial fibrillation (AF) and a bioprosthetic mitral valve, published in the Annals of Internal Medicine.